BofA raised the firm’s price target on Agilent (A) to $130 from $128 and keeps a Neutral rating on the shares. While there has been some stabilization and/or improvement in some areas of Life Sciences and Diagnostic Tools, several pockets of uncertainty and softness over the past year remain and are likely to persist for at least the next few quarters, says the analyst, who is trimming forecasts for many core Tools companies and now anticipates a more gradual return to “normal.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A:
- Agilent pharmDx receives EU class C companion diagnostic certification
- Agilent Technologies Surpasses Expectations in Q3 Earnings Call
- Agilent Technologies Grapples with Regulatory and Sustainability Challenges Impacting Financial Stability
- Early notable gainers among liquid option names on August 28th
- Agilent price target raised to $142 from $141 at Baird